---
title: "Pharmaceutical stocks show divergence during trading, with Cosunter experiencing a significant drop"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253565001.md"
description: "Pharmaceutical stocks showed divergence during the session, with Cosunter plunging nearly 10%, while InnoCare Pharma, SMOC, SHANGHAI YIZHONG, and Innovative Medical all saw significant declines"
datetime: "2025-08-19T05:32:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253565001.md)
  - [en](https://longbridge.com/en/news/253565001.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253565001.md)
generator: "portal-rs"
---

# Pharmaceutical stocks show divergence during trading, with Cosunter experiencing a significant drop

Pharmaceutical stocks showed divergence during trading, with Cosunter plunging nearly 10%, while InnoCare Pharma, SMOC, SHANGHAI YIZHONG, and Innovative Medical all saw significant declines

### Related Stocks

- [688091.CN](https://longbridge.com/en/quote/688091.CN.md)
- [002173.CN](https://longbridge.com/en/quote/002173.CN.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688265.CN](https://longbridge.com/en/quote/688265.CN.md)
- [300436.CN](https://longbridge.com/en/quote/300436.CN.md)

## Related News & Research

- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Dino Polska S.A. (WSE:DNP) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/296763667.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**